Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Prime Medicine (PRME) Return on Invested Capital (2022 - 2025)

Prime Medicine (PRME) has disclosed Return on Invested Capital for 4 consecutive years, with 1.59% as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Return on Invested Capital fell 46.0% year-over-year to 1.59%, compared with a TTM value of 1.59% through Mar 2025, down 46.0%, and an annual FY2023 reading of 0.91%, up 54.0% over the prior year.
  • Return on Invested Capital was 1.59% for Q1 2025 at Prime Medicine, down from 1.01% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.67% in Q3 2022 and bottomed at 2.48% in Q4 2022.
  • Average Return on Invested Capital over 4 years is 0.96%, with a median of 1.01% recorded in 2024.
  • Peak annual rise in Return on Invested Capital hit 123bps in 2023, while the deepest fall reached -148bps in 2023.
  • Year by year, Return on Invested Capital stood at 2.48% in 2022, then surged by 50bps to 1.25% in 2023, then increased by 19bps to 1.01% in 2024, then crashed by -56bps to 1.59% in 2025.
  • Business Quant data shows Return on Invested Capital for PRME at 1.59% in Q1 2025, 1.01% in Q2 2024, and 1.13% in Q1 2024.